Results 51 to 60 of about 122,145 (339)

The role of ECL2 in CGRP receptor activation: a combined modelling and experimental approach [PDF]

, 2013
The calcitonin gene-related peptide (CGRP) receptor is a complex of a calcitonin receptor-like receptor (CLR), which is a family B G-protein-coupled receptor (GPCR) and receptor activity modifying protein 1.
Alex C. Conner, Barwell J, Bruck Taddese, Christopher A. Reynolds, Conner AC, David R. Poyner, Debbie L. Hay, Harriet A. Watkins, James Barwell, Kevin J. Smith, Michael. J. Woolley, Urano D, Watkins HA, Z. Gamze Karakullukcu   +13 more
core   +2 more sources

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine [PDF]

, 2019
Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control, it is often necessary to rely on combination therapy of multiple drugs or insulin because uncontrolled ...
Andreozzi, F, Mannino, Gc, Sesti, G
core   +1 more source

The effects of species ortholog and SNP variation on receptors for free fatty acids [PDF]

, 2013
Although it is widely assumed that species orthologs of hormone responsive G protein-coupled receptors will be activated by the same endogenously produced ligand(s), variation in potency, particularly in cases where more than one receptor responds to the
1000 Genomes Project Consortium, Bellahcene, Bergman, Bjursell, Blad, Brian D. Hudson, Briscoe, Brown, Burant, Christiansen, Christiansen, Christiansen, Christiansen, Cummings, Edfalk, Fredriksson, Galindo, Ge, Graeme Milligan, Hamid, Hannah Murdoch, Hirasawa, Hong, Hudson, Hudson, Hudson, Hudson, Humphries, Ichimura, Insel, Itoh, Kaku, Kalis, Kebede, Kebede, Kimura, Lan, Latour, Le Poul, Leonard, Liaw, Lin, Luo, Maslowski, Milligan, Milligan, Moore, Negoro, Ogawa, Oh, Ryan, Sawzdargo, Schmidt, Shimpukade, Sina, Smith, Smith, Steneberg, Stoddart, Stoddart, Strasser, Sum, Tan, Taneera, Tolhurst, Vettor, Watson, Wolever, Xiong, Xiong, Yashiro, Zaibi, Zhou   +72 more
core   +1 more source

Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care

Journal of Personalized Medicine, 2022
The available data suggest differences in the course of type 2 diabetes mellitus (T2DM) between men and women, influenced by the distinguishing features of the sex.
Elpiniki Rentzeperi, Stavroula Pegiou, T. Koufakis, M. Grammatiki, K. Kotsa   +4 more
semanticscholar   +1 more source

When intensive insulin therapy (MDi) fails in patients with type 2 diabetes: Switching to GLP-1 receptor agonist versus insulin pump [PDF]

, 2016
Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is becoming increasingly common in patients with type 2 diabetes. However, approximately 40% of patients fail to reach their glycemic targets with the initially prescribed ...
Castaneda, Javier, Cohen, Ohad, FILETTI, SEBASTIANO, Glandt, Mariela, MARANGHI, MARIANNA   +4 more
core   +2 more sources

Clinical pharmacology of glucagon-like peptide-1 receptor agonists

Hormones, 2018
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important asset in the armamentarium for the treatment of type 2 diabetes mellitus (type 2 DM). Incretin failure is a critical etiopathogenetic feature of type 2 DM, which, if reversed, results in improved glycaemic control.
Sfairopoulos, D., Liatis, S., Tigas, S., Liberopoulos, E.   +3 more
openaire   +3 more sources

Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling [PDF]

, 2013
It has been estimated that approximately 8.4% of the world population currently live with diabetes mellitus and type 2 diabetes is the most common form. Type 2 diabetes increases the risk of complications such as heart attacks, blindness, amputations and
Venkat Kanamarlapudi
core   +1 more source

Cutting Edge Developments in Diabetes

Diabetology, 2023
Since 2005, glucagon-like peptide 1 (GLP-1) receptor agonists have been clinically available, which has resulted in a significant transformation in diabetes care, both in terms of weight management and glucose control [...]
Peter M. Clifton
doaj   +1 more source

Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson’s disease

Neural Regeneration Research
Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of type 2 diabetes mellitus, have been suggested as a potential disease-modifying treatment for Parkinson’s disease.
Shangqi Sun, Liqin Huang, Gege Jiang, Guanfeng Xie, Xiaoyi Li, Xiufeng Wang, Hongxiu Guo, Cailin Wang, Siyi Zheng, Gang Li, Jing Xiong   +10 more
doaj   +1 more source

Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement

Anaesthesia
Glucagon‐like peptide‐1 receptor agonists, dual glucose‐dependent insulinotropic peptide receptor agonists and sodium‐glucose cotransporter‐2 inhibitors are used increasingly in patients receiving peri‐operative care.
K. El-Boghdadly, J. Dhesi, Philippa Fabb, N. Levy, D. Lobo, A. McKechnie, Omar G Mustafa, P. Newland-Jones, Anil Patel, D. Pournaras, K. Clare, K. Dhatariya   +11 more
semanticscholar   +1 more source